celecoxib + vortioxetine

Celecoxib + vortioxetine is a combination of two small molecule drugs investigated for the treatment of major depressive disorder (MDD), particularly in patients with evidence of low-grade inflammation. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a non-steroidal anti-inflammatory drug (NSAID), while vortioxetine is an antidepressant that acts as a serotonin modulator and stimulator. The rationale for this combination stems from evidence suggesting that inflammation may contribute to the pathophysiology of depression in some patients, and that anti-inflammatory agents like celecoxib could augment antidepressant efficacy. However, clinical trials have not demonstrated superior efficacy for this combination over standard antidepressant therapy alone in MDD, including among those with elevated inflammatory markers[1][2][3][6].